Figure 1: 2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide (example 1) as an inhibitor of HBeAg production in HepDE19 cells.




Figure 2: 2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide (Example 1) reduces the levels of HBV cccDNA and DP-rcDNA in cell cultures.




Figure 3: 2-[Benzenesulfonyl-(2-chloro-5-trifluoromethyl-phenyl)-amino]-N-pyridin-4-ylmethyl-acetamide (Example 1) does not inhibit viral polymerase activity.





Figure 4: 4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-benzothiazol-5-yl)-benzamide (example 1) as an inhibitor of HBeAg production in HepDE19 cells.



MW= 451.56
cLogP = 4.81
pKa= 2.78+/-0.3




Figure 5: 4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-benzothiazol-5-yl)-benzamide (example 1) reduces the levels of cccDNA and DP-rcDNA in cell cultures.




Figure 6: 4-(Benzyl-methyl-sulfamoyl)-N-(2-methyl-benzothiazol-5-yl)-benzamide (example 1) does not inhibit viral polymerase activity at 3 μM.

